HONG KONG, Mar 3, 2022 - (ACN Newswire via SEAPRWire.com) - Yeahka Limited ("Yeahka" or the "Company") (09923.HK) has announced a donation of 60,000 antigen rapid test kits to support Hong Kong's fight against the increasingly serious outbreak of Covid-19.The antigen rapid test kits will be donated to Po Leung Kuk and distributed to the elderly and disabled through its elderly service units and rehabilitation service units respectively, helping them monitor their health status in real time. The fifth wave of the pandemic has proven challenging for Hong Kong, with the number of new daily COVID-19 infections hitting record highs. In the face of the severe pandemic situation, there is an increase in demand for pandemic prevention resources. Yeahka has been closely monitoring the pandemic situation in Hong Kong and hopes the initiative will help, sending love and care to the people in need. About YEAHKA LIMITED (Stock Code: 9923.HK)Yeahka, listed on the Main Board of Hong Kong Stock Exchange in 2020, is a leading payment-based technology platform dedicated to creating value for merchants and consumers by providing one-stop payment services and diversified technology-enabled business services. According to Analysys's report in 2022, Yeahka ranks No.1 in the non-bank, Independent QR code payment service market in China. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
ADELAIDE, AUS, Aug 26, 2021 - (ACN Newswire via SEAPRWire.com) - Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on "Non-clinical and clinical pathways for rapid vaccine development in Australia", in a webinar hosted by Endpoints News Editor Arsalan Arif.Agilex Biolabs' Director, Immunoassay, Kurt J. Sales (B.Sc; B.Sc (MED) Hons; M.Sc, Ph.D, PGCM) said:"The COVID-19 pandemic has seen the rapid development of a series of novel vaccines targeting SARS-CoV-2. Development of multiple COVID-19 vaccine candidates has been facilitated within Australia by the availability of high-quality contract research organizations such as Agilex Biolabs, and a favorable regulatory environment. This webinar will cover the pathways that biotech companies can take for rapid vaccine development, and why Australia is the ideal location. I am joined by my toxicology expert colleagues Dr Peter Tapley and Dr Drew Brockman for this detailed vaccine development webinar."In this webinar Dr Sales and specialists from Agilex Biolabs' toxicology firm, TetraQ Toxicology will provide an overview of strategies to conduct vaccine development within Australia.It will cover Australian research, and regulatory and clinical infrastructure, which provides a favorable environment for rapid vaccine development. It will also include discussion of a case study for rapid vaccine development based on non-clinical research conducted with a novel COVID-19 protein subunit vaccine.This case study will review key aspects of non-clinical design required to facilitate approval for first-in-human studies.Register Here: https://webinars.endpts.com/non-clinical-and-clinical-pathways-for-rapid-vaccine-development-in-australia/September 7, 2:00 pm - 3:00 pm EDTSpeakers:Dr Kurt Sales: Director, Immunoassay, Agilex BiolabsDr Peter Tapley: Director, TetraQ, an Agilex Biolabs companyDr Drew Brockman: Head of Toxicology, TetraQ, an Agilex Biolabs company.https://webinars.endpts.com/non-clinical-and-clinical-pathways-for-rapid-vaccine-development-in-australia/Agilex Biolabs' world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and soon to be released, digital droplet quantitative real-time RT-PCR.Latest News - new Immunobiology Lab - watch launch video. https://www.agilexbiolabs.com/launch-of-immunobiology-laboratory/Agilex Biolabs CEO Jason Valentine said the new laboratory focusses on new and emerging areas of therapeutic interest, including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies."This new facility adds digital droplet quantitative RT-PCR analysis for RNA, siRNA and miRNA clinical trials, including vaccines and gene therapy trials," he said."We are also installing an EliSPOT/FluoroSPOT multi-spot reader for vaccine studies to enable extrapolation of recall immune responses, which coupled with our state-of-the-art BD FACSymphony 5 laser, 20 colour flow cytometer, offers unparalleled sensitivity for immunology and vaccine trials."The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.Agilex Biolabs has more than 130 staff which includes 85 dedicated laboratory staff, and supports client pharma and biotech companies from US, Europe and APAC.Book a confidential briefing with our scientists before you start your next clinical trial. https://calendly.com/agilexbiolabs/30minAbout Agilex Biolabs https://www.agilexbiolabs.com/Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials, has more than 24 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. It has successfully supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.Agilex Biolabs also offers toxicology services through its company TetraQ, an established GLP toxicology facility in Australia.Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.The company has recently expanded its main labs by more than 30% to accommodate biotech demand from APAC and the USA. In addition it has launched a new Immunobiology lab - watch the video here. https://www.agilexbiolabs.com/launch-of-immunobiology-laboratory/Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including: - Immunophenotyping- Receptor occupancy- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling- PBMC assays and cellular mechanism of action assays Agilex Biolabs Media Contact:Kate NewtonMedia@AgilexBiolabs.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)
SINGAPORE - For pre-event testing, the Ministry of Health recommends an antigen rapid test, as it is cheaper and faster than the polymerase chain reaction test. Antigen rapid tests usually take less than 30 minutes, while a polymerase chain reaction test, though more accurate, can take up to 48 hours. For large events requiring pre-event testing, the ministry allows organisers to arrange for antigen rapid tests for attendees at a clinic, or hire an approved test provider to conduct the tests at the event venue. Organisers can also require attendees to go for an antigen rapid test on their own at an approved clinic. Dr Stephen Tong, medical director at Bethesda Medical Centre, which provides antigen rapid tests, said that to conduct a large number of tests on-site, certain conditions must be met. He said the test site will need separate areas for registration, swabbing, sample processing, waiting for results and isolating those tested positive, plus areas for staff to put on and remove medical attire, and a biohazard waste area. The site must have a separate entrance and exit, and enough space for safe distancing. Dr Tong estimates that 13 staff are needed to complete antigen rapid tests for 250 people in two hours, and about triple the manpower to test 750 people in the same amount of time. The Health Ministry said on its website that pre-event testing is necessary to reduce risks of positive Covid-19 cases at events so that more activities can resume safely. After obtaining a negative result, the test provider will issue a Covid-19 test result notice to the attendee. This must be shown with a valid photo identification to gain entry into events that require pre-event testing. The test must have been administered no more than 24 hours before the end of the event. If the antigen rapid test is positive or invalid, this may suggest Covid-19 infection but could also be a false positive. If this happens, the Health Ministry requires a confirmatory polymerase chain reaction test as soon as possible. Attendees should ask the organiser whether they would receive a refund if they miss the event due to a positive or invalid antigen rapid test result. More on this topic Related Story Pre-event Covid-19 testing: Logistics, cost among concerns for couples and event organisers Related Story How do Covid-19 antigen rapid tests work and how will they be used?
Epalinges, Switzerland, Dec 18, 2020 - (ACN Newswire) - Swiss high-tech company ZENUM has developed one of the most advanced technologies in the fight against Covid-19, and it could be ready for distribution as early as next month. The world's first five-minute portable Coronavirus test will also detect how much immunity remains after taking a vaccine. NANOFLUIDIC RAPID TEST KIT - Identify from a drop of blood whether a person's Covid-19 vaccine is still valid - in 5 Minutes! ZENUM SWITZERLAND 2021The game-changing ZEKNANO rapid test kit uses a tiny finger-prick blood sample, instead of swabs. It can be taken anywhere, has close to 100% accuracy, and also measures severity of infection. Thanks to nanotechnology, ZEKNANO not only detects Covid-19 within five minutes, but it identifies up to 14 different conditions simultaneously, including flu virus and infectious diseases.Artificial Intelligence (AI) is at the heart of the revolutionary product. A neural network - a series of algorithms designed to function like a human brain - has been added to increase the test's efficiency, and study any mutation of the virus.As the device is portable and lightweight, the tests do not have to be administered only in medical settings. This makes it a leading contender to tackle coronavirus and other diseases in the developing world. It also has the potential to help control the pandemic across all countries before another possible surge in the coming months.ZENUM already produces 15-minute coronavirus rapid test kits for antibodies and antigens, under the brand ZEKMED. The performance evaluation of these kits were conducted by CIRION Biopharma, one of the few CLIA laboratories in Canada. The results are in accordance with three independent evaluations conducted in Russia, Switzerland and France.The new ZEKNANO five-minute test is expected to be certified for use in January, putting it ahead of several ongoing projects to achieve such rapid results.Emidio Do Sacramento, founder and CEO of ZENUM, said: "It doesn't matter if it's a 5 or 15 minute rapid test. Our focus is to help practitioners and health institutions, the best we can, to save lives."The reality is that the world is in need of products that solve a problem, and not a marketing sales campaign promoting companies or universities, whether that product is from our company or any other."Enough is enough. Mass testing, fast and accurate patient triage is the only reliable solution before any vaccine reaches enough people. We need our lives and economy back to 'normal'."About ZENUMZENUM's origins are rooted in a collaborative network of innovators who strive in the development of applications/mediums/security using biometrics, Ai and blockchain technologies and the infinite influences these technologies will have on life. As a result of our developments in these fields with our project collaborators and likeminded partners, we found ourselves already engaged and working in the field of medical pre-diagnosis using biometric data for example the research into the pre-diagnosis of glaucoma.ZENUM is located in new facilities at BIOPOLE, the Life Sciences Campus - one of the largest healthcare research campuses in Europe, and has important medical partnerships in Switzerland, Germany and China. Full technical details can be found at https://zekmed.com/zeknano.htmlFor more information, please contact:Emidio Do Sacramento, CEO, ZenumE: es@zenum.swiss, es@zekmed.com, https://zekmed.comAbout the CEO:https://tinyurl.com/Forbes-Sacramentohttps://www.linkedin.com/in/emidiosacramento/https://www.linkedin.com/company/zenum-technologies/ Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).For further information, please contact:Prof Dr. Aulanni'am, drh., DES+62 812-3317-600Public Relations,Universitas Brawijayawww.ub.ac.idwww.prasetya.ub.ac.id Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.